The Bcl-2 apoptotic switch in cancer development and therapy

2,202 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Mitochondrial dynamics and apoptosis. (2008, background): “Bcl-2 family proteins regulate the release of cytochrome c and other proteins through the outer mitochondrial membrane (OMM) (Adams and Cory 2007; Chipuk and Green 2008).”
Selectivity by Small-Molecule Inhibitors of Protein Interactions Can Be Driven by Protein Surface Fluctuations (2015, neutral): “The critical step of disregulating apoptosis in tumor maintenance and chemoresistance has made certain members of this family exceptionally attractive targets for therapeutic intervention for many years, and in a variety of cancers [17].”
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies (2016, background): “Therefore, by mediating permeabilization of the mitochondrial membrane, the Bcl-2 proteins serve as an “apoptotic switch” [30].”
Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “It is now clear that, through its dual role, cyclin E provides a physiological balance between cell proliferation and death of hematopoietic cells [161].”
Tumor resistance to apoptosis (2009, background): “cates to mitochondria upon cleavage and causes cytochrome c release.(7) The mitochondrial pathway is initiated by the release of”
Role of Bcl-2 family proteins and caspases in the regulation of apoptosis (2011, background): “Apoptosis or PCD has conserved genetic and biochemical pathways [27, 101].”